DK1473294T3 - Substituerede1,3-oxathiolaner med antivirale egenskaber - Google Patents

Substituerede1,3-oxathiolaner med antivirale egenskaber

Info

Publication number
DK1473294T3
DK1473294T3 DK04018075T DK04018075T DK1473294T3 DK 1473294 T3 DK1473294 T3 DK 1473294T3 DK 04018075 T DK04018075 T DK 04018075T DK 04018075 T DK04018075 T DK 04018075T DK 1473294 T3 DK1473294 T3 DK 1473294T3
Authority
DK
Denmark
Prior art keywords
oxathiolanes
substituted
antiviral properties
relates
fluorocytosine
Prior art date
Application number
DK04018075T
Other languages
English (en)
Inventor
Tarek S Mansour
Haolun Jin
Original Assignee
Shire Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Biochem Inc filed Critical Shire Biochem Inc
Application granted granted Critical
Publication of DK1473294T3 publication Critical patent/DK1473294T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
DK04018075T 1994-04-20 1995-04-19 Substituerede1,3-oxathiolaner med antivirale egenskaber DK1473294T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/230,317 US5587480A (en) 1990-11-13 1994-04-20 Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
PCT/CA1995/000212 WO1995029176A1 (en) 1994-04-20 1995-04-19 Substituted 1,3-oxathiolanes with antiviral properties

Publications (1)

Publication Number Publication Date
DK1473294T3 true DK1473294T3 (da) 2007-09-17

Family

ID=22864746

Family Applications (3)

Application Number Title Priority Date Filing Date
DK04018075T DK1473294T3 (da) 1994-04-20 1995-04-19 Substituerede1,3-oxathiolaner med antivirale egenskaber
DK95915098T DK0756595T3 (da) 1994-04-20 1995-04-19 Substituerede 1,3-oxathiolaner med antivirale egenskaber
DK02004883.1T DK1224940T4 (da) 1994-04-20 1998-09-23 Flydende formuleringer af interferon-beta

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK95915098T DK0756595T3 (da) 1994-04-20 1995-04-19 Substituerede 1,3-oxathiolaner med antivirale egenskaber
DK02004883.1T DK1224940T4 (da) 1994-04-20 1998-09-23 Flydende formuleringer af interferon-beta

Country Status (12)

Country Link
US (1) US5587480A (da)
EP (3) EP1473294B1 (da)
JP (1) JPH09512526A (da)
AT (3) ATE360019T1 (da)
AU (1) AU693884B2 (da)
CA (1) CA2188283C (da)
DE (3) DE69525742T2 (da)
DK (3) DK1473294T3 (da)
ES (3) ES2286542T3 (da)
HK (3) HK1005544A1 (da)
PT (3) PT1153924E (da)
WO (1) WO1995029176A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346627B1 (en) 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6228860B1 (en) * 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
US6369066B1 (en) 1990-11-13 2002-04-09 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes with antiviral properties
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
EP1655033A1 (en) * 1995-06-07 2006-05-10 Emory University Nucleosides with anti-hepatitis B virus activity
CN1141305C (zh) 1998-08-12 2004-03-10 三角药物公司 生产1,3-氧硫戊环核苷的方法
US6979561B1 (en) * 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
WO2001058920A2 (fr) * 2000-02-10 2001-08-16 Mitsui Chemicals, Inc. Procede de production selective d'un anomere derive d'un sucre 1-phosphoryle
WO2002051852A1 (fr) * 2000-12-27 2002-07-04 Mitsui Chemicals, Inc. Procede de production d'un derive de saccharide non naturel
SI1632490T1 (sl) * 2001-06-15 2008-02-29 Shire Biochem Inc Stereoselektivna metoda za pripravo nukleozidnih analogov
EP1583542B9 (en) 2003-01-14 2008-10-22 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US7501514B1 (en) 2003-10-15 2009-03-10 Shire Biochem, Inc. Enantiomeric resolution of 2-substituted 4-substituted 1,3-oxathiolanes nucleosides
US7968703B2 (en) * 2005-03-07 2011-06-28 Shire Canada Inc. Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof
BRPI0520041A2 (pt) * 2005-03-14 2009-04-14 Shire Biochem Inc processo e métodos para a preparação de cis-2-hidroximetil-4- ( citosin-1' - il) - 1,3-oxatiolano oticamente ativo ou sais derivados farmaceuticamente aceitáveis
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
US20080249066A1 (en) * 2007-03-23 2008-10-09 Ardea Biosciences, Inc. Antiviral compounds and compositions
NZ584193A (en) * 2007-09-28 2011-07-29 Avexa Ltd A process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes
CN102203111B (zh) 2008-09-05 2014-08-20 塞尔加拿大有限公司 2,4-二取代的1,3 -氧硫杂环戊烷核苷的对映体拆分
US8153416B2 (en) 2008-12-10 2012-04-10 Thesis Chemistry, Llc Process for manufacture of optically active 2-(acyloxymethyl)-1,3-oxathiolanes using enzymatic resolution
US8431699B2 (en) 2009-02-27 2013-04-30 Vertichem Corporation Method for manufacture of 2-oxoimidazolidines
TW201131192A (en) * 2010-03-01 2011-09-16 Univ Nat Central A co-crystal compound of optical devices
AU2012324008A1 (en) * 2011-11-18 2013-06-06 Avexa Limited Apricitabine and PI combination therapy
JP2012136526A (ja) * 2012-02-09 2012-07-19 Shire Canada Inc 光学的に活性なｃｉｓ−２−ヒドロキシメチル−４−（シトシン−１’−イル）−１，３−オキサチオランまたはその薬学的に許容される塩の製造方法
WO2024016639A1 (zh) * 2022-07-21 2024-01-25 华创合成制药股份有限公司 一种抗病毒感染的化合物及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
DE3529263A1 (de) * 1985-08-16 1987-02-19 Hoechst Ag Verfahren zur herstellung von 2-oxo-1,3-dioxolanen
US5159067A (en) * 1987-01-28 1992-10-27 University Of Georgia Research Foundation Inc. 5'-Diphosphohexose nucleoside pharmaceutical compositions
SE8701605D0 (sv) * 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds
US5039667A (en) * 1987-08-07 1991-08-13 The Governors Of The University Of Alberta Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucleosides
US4997926A (en) * 1987-11-18 1991-03-05 Scripps Clinic And Research Foundation Deaminase-stable anti-retroviral 2-halo-2',3'-dideoxy
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
DE3827134A1 (de) * 1988-08-10 1990-03-15 Bayer Ag Substituierte triazolyl- bzw. imidazolyl-hydroxyalkyldioxolane, verfahren zu ihrer herstellung und ihre verwendung als mikrobizide, oxiranyldioxolane, dioxolanylketone, oxiranylketone und (alpha)-halogenketone als zwischenprodukte und verfahren zu deren herstellung
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5118672A (en) * 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
NZ234534A (en) * 1989-07-17 1994-12-22 Univ Birmingham Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor
DK0560794T3 (da) * 1990-11-13 1996-12-23 Iaf Biochem Int Substituerede 1,3-oxathiolaner med antivirale egenskaber
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides

Also Published As

Publication number Publication date
HK1041487A1 (en) 2002-07-12
HK1005544A1 (en) 1999-01-15
DK1224940T3 (da) 2004-12-27
ES2172580T3 (es) 2002-10-01
DE69533458D1 (de) 2004-10-07
CA2188283C (en) 2003-11-04
EP0756595A1 (en) 1997-02-05
DE69535476T2 (de) 2008-01-03
EP1473294A3 (en) 2004-11-17
EP0756595B1 (en) 2002-03-06
EP1153924A2 (en) 2001-11-14
EP1153924A3 (en) 2001-11-21
DE69525742D1 (de) 2002-04-11
DK1224940T4 (da) 2010-10-25
HK1073460A1 (en) 2005-10-07
DE69525742T2 (de) 2002-09-26
ES2228714T3 (es) 2005-04-16
WO1995029176A1 (en) 1995-11-02
ATE360019T1 (de) 2007-05-15
DE69535476D1 (de) 2007-05-31
EP1473294A2 (en) 2004-11-03
HK1041487B (zh) 2005-01-07
JPH09512526A (ja) 1997-12-16
PT1473294E (pt) 2007-06-11
PT1153924E (pt) 2005-01-31
EP1473294B1 (en) 2007-04-18
PT756595E (pt) 2002-08-30
DK0756595T3 (da) 2002-06-17
AU693884B2 (en) 1998-07-09
ATE214066T1 (de) 2002-03-15
US5587480A (en) 1996-12-24
ATE275144T1 (de) 2004-09-15
EP1153924B1 (en) 2004-09-01
DE69533458T2 (de) 2005-10-27
CA2188283A1 (en) 1995-11-02
ES2286542T3 (es) 2007-12-01
AU2211895A (en) 1995-11-16

Similar Documents

Publication Publication Date Title
DK1473294T3 (da) Substituerede1,3-oxathiolaner med antivirale egenskaber
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
SE9604786D0 (sv) New compounds
EP0324387A3 (en) Composition for treatment of ischemic disorder in organs
PH25571A (en) Alpha'-alkyl-4-amino-3-quinolinemethanols, 1-(4-aralkylamino-3-quinolinyl) alaknones, their use as medicaments
ATE147071T1 (de) 1,4-disubstituierte piperidinderivate, ihre herstellung und therapeutische verwendung
DK0573218T3 (da) 4-carboxyimidazolderivater som angiotensin-II antagonister og deres terapeutiske anvendelse
IE893956L (en) Novel compounds
ES8707951A1 (es) Derivados de tetrazol
ATE58135T1 (de) 1,3-oxathianderivate.
ES8802507A1 (es) Procedimiento para preparar eteres 1,3-dioxano.
FI873145A (fi) Nya tetracykliska indolderivat.